Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United TherapeuticsUTHR -0.23%88 EV-to-EBIT is 11.88 as of Jul. 26, 2026, which is 58% above its 10-year median of 7.53. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.15 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, United Therapeutics ranks better than 62.03% on this metric.
United Therapeutics (NAS:UTHR) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
United Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $22,844 Mil.
United Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,625 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics EV-to-EBIT Related Terms
United Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for United Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-EBIT falls into.
United Therapeutics's current Enterprise Value is $19,304 Mil.
United Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,625 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a EV-to-EBIT of 11.88 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on United Therapeutics and its competitors. This is 58% above median its historical median of 7.53. According to the industry distribution chart, United Therapeutics ranks #262 out of 690 companies in the Drug Manufacturers industry, placing it in the top 38%.
Is United Therapeutics' EV-to-EBIT too high?
United Therapeutics' current EV-to-EBIT of 11.88 is 58% above median its 10-year median of 7.53. The Drug Manufacturers industry median EV-to-EBIT is 15.42. United Therapeutics' value of 11.88 is 23% below this industry median. Based on the distribution chart, United Therapeutics ranks #262 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EV-to-EBIT compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #262 out of 690 companies for EV-to-EBIT. This puts United Therapeutics in the upper half of its industry. The industry median EV-to-EBIT is 15.42. United Therapeutics' value of 11.88 is 23% below this benchmark. While the company's 10-year median is 7.53 vs. the industry median of 15.42, United Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current EV-to-EBIT of 11.88 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current EV-to-EBIT is 11.88, which is 58% above median its own 10-year median of 7.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.15, compared to a current price of $528.31 — trading 36.5% above its estimated fair value. The current EV-to-EBIT is 11.88, which is 58% above median its 10-year median of 7.53 and 23% below the Drug Manufacturers industry median of 15.42. United Therapeutics' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For United Therapeutics (UTHR), the current EV-to-EBIT is 11.88 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $528.31 is trading 36.5% above its estimated GF Value™ of $387.15.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
EV-to-EBIT: 11.88 (58% above median its 10-year median of 7.53)
GF Value™: $387.15 vs. price of $528.31 (36.5% above fair value)
Industry Position: 23% below the Drug Manufacturers median (#262 of 690)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
